GB201513742D0 - Muscarinic agonists - Google Patents
Muscarinic agonistsInfo
- Publication number
- GB201513742D0 GB201513742D0 GBGB1513742.5A GB201513742A GB201513742D0 GB 201513742 D0 GB201513742 D0 GB 201513742D0 GB 201513742 A GB201513742 A GB 201513742A GB 201513742 D0 GB201513742 D0 GB 201513742D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- muscarinic agonists
- muscarinic
- agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000472 muscarinic agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513742.5A GB201513742D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonists |
| ES16750223T ES2850298T3 (es) | 2015-08-03 | 2016-08-03 | Agonistas muscarínicos |
| JP2018504985A JP6876675B2 (ja) | 2015-08-03 | 2016-08-03 | ムスカリンアゴニスト |
| UAA201801267A UA123315C2 (uk) | 2015-08-03 | 2016-08-03 | Агоністи мускаринових рецепторів |
| HK18109575.4A HK1250160B (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| MYPI2018000148A MY195244A (en) | 2015-08-03 | 2016-08-03 | Muscarinic Agonists |
| CN201680043661.XA CN107949558B (zh) | 2015-08-03 | 2016-08-03 | 毒蕈碱激动剂 |
| BR112018002279-9A BR112018002279B1 (pt) | 2015-08-03 | 2016-08-03 | Compostos agonistas muscarinícos, composição farmacêutica e usos terapêuticos dos mesmos |
| CA2993484A CA2993484C (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| EP16750223.6A EP3331869B1 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| ES20213929T ES2980578T3 (es) | 2015-08-03 | 2016-08-03 | Agonistas muscarínicos |
| PCT/GB2016/052386 WO2017021730A1 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| DK16750223.6T DK3331869T3 (da) | 2015-08-03 | 2016-08-03 | Muscarinagonister |
| TW105124670A TWI723037B (zh) | 2015-08-03 | 2016-08-03 | 毒蕈鹼促效劑 |
| KR1020187006156A KR102664558B1 (ko) | 2015-08-03 | 2016-08-03 | 무스카린성 작용제 |
| RU2018105020A RU2737158C2 (ru) | 2015-08-03 | 2016-08-03 | Агонисты мускариновых рецепторов |
| MX2018001564A MX379530B (es) | 2015-08-03 | 2016-08-03 | Compuestos agonistas del receptor muscarínico m4. |
| EP20213929.1A EP3822262B1 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| AU2016302048A AU2016302048B2 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| ARP160102378A AR105593A1 (es) | 2015-08-03 | 2016-08-03 | Agonistas muscarínicos |
| US15/227,325 US9758506B2 (en) | 2015-08-03 | 2016-08-03 | Muscarinic agonists |
| US15/699,674 US10351545B2 (en) | 2015-08-03 | 2017-09-08 | Muscarinic agonists |
| IL257064A IL257064A (en) | 2015-08-03 | 2018-01-21 | muscarinic agonists |
| US15/886,057 US10167272B2 (en) | 2015-08-03 | 2018-02-01 | Muscarinic agonists |
| CL2018000292A CL2018000292A1 (es) | 2015-08-03 | 2018-02-01 | Compuestos farmacéuticos |
| ZA2018/00715A ZA201800715B (en) | 2015-08-03 | 2018-02-02 | Muscarinic agonists |
| PH12018500259A PH12018500259A1 (en) | 2015-08-03 | 2018-02-02 | Muscarinic agonists |
| CONC2018/0002060A CO2018002060A2 (es) | 2015-08-03 | 2018-02-26 | Compuestos farmacéuticos |
| US16/418,354 US11091456B2 (en) | 2015-08-03 | 2019-05-21 | Muscarinic agonists |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513742.5A GB201513742D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201513742D0 true GB201513742D0 (en) | 2015-09-16 |
Family
ID=54063148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1513742.5A Ceased GB201513742D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonists |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9758506B2 (enExample) |
| EP (2) | EP3822262B1 (enExample) |
| JP (1) | JP6876675B2 (enExample) |
| KR (1) | KR102664558B1 (enExample) |
| CN (1) | CN107949558B (enExample) |
| AR (1) | AR105593A1 (enExample) |
| AU (1) | AU2016302048B2 (enExample) |
| BR (1) | BR112018002279B1 (enExample) |
| CA (1) | CA2993484C (enExample) |
| CL (1) | CL2018000292A1 (enExample) |
| CO (1) | CO2018002060A2 (enExample) |
| DK (1) | DK3331869T3 (enExample) |
| ES (2) | ES2850298T3 (enExample) |
| GB (1) | GB201513742D0 (enExample) |
| IL (1) | IL257064A (enExample) |
| MX (1) | MX379530B (enExample) |
| MY (1) | MY195244A (enExample) |
| PH (1) | PH12018500259A1 (enExample) |
| RU (1) | RU2737158C2 (enExample) |
| TW (1) | TWI723037B (enExample) |
| UA (1) | UA123315C2 (enExample) |
| WO (1) | WO2017021730A1 (enExample) |
| ZA (1) | ZA201800715B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| KR102229608B1 (ko) | 2015-08-03 | 2021-03-19 | 아이크노스 사이언스 에스. 아. | Ror 감마 조절제로서의 신규한 화합물 |
| EA033686B1 (ru) | 2015-08-03 | 2019-11-15 | Bristol Myers Squibb Co | Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| TW201726675A (zh) | 2015-12-23 | 2017-08-01 | 默沙東藥廠 | M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮 |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019027860A1 (en) * | 2017-08-01 | 2019-02-07 | Boehringer Ingelheim International Gmbh | INTERMEDIATE COMPOUNDS AND METHODS |
| AU2018352828A1 (en) * | 2017-10-17 | 2020-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| PT3768669T (pt) * | 2018-03-23 | 2023-04-24 | Pfizer | Derivados de piperazina azaspiro |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN119390705A (zh) | 2019-10-09 | 2025-02-07 | 诺华股份有限公司 | 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物 |
| WO2021070090A1 (en) * | 2019-10-09 | 2021-04-15 | Novartis Ag | 2-azaspiro[3.4]octane derivatives as m4 agonists |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080098070A (ko) * | 2006-02-22 | 2008-11-06 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘 |
| UY31672A1 (es) * | 2008-02-28 | 2009-09-30 | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| WO2011112825A2 (en) * | 2010-03-10 | 2011-09-15 | Vanderbilt University | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| CN107098899B (zh) * | 2012-09-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 作为毒蕈碱的m1受体激动剂的二环氮杂化合物 |
| SG11201606269WA (en) | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| KR102229608B1 (ko) | 2015-08-03 | 2021-03-19 | 아이크노스 사이언스 에스. 아. | Ror 감마 조절제로서의 신규한 화합물 |
| EA033686B1 (ru) | 2015-08-03 | 2019-11-15 | Bristol Myers Squibb Co | Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| AR105556A1 (es) | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
-
2015
- 2015-08-03 GB GBGB1513742.5A patent/GB201513742D0/en not_active Ceased
-
2016
- 2016-08-03 MY MYPI2018000148A patent/MY195244A/en unknown
- 2016-08-03 AR ARP160102378A patent/AR105593A1/es unknown
- 2016-08-03 WO PCT/GB2016/052386 patent/WO2017021730A1/en not_active Ceased
- 2016-08-03 BR BR112018002279-9A patent/BR112018002279B1/pt active IP Right Grant
- 2016-08-03 UA UAA201801267A patent/UA123315C2/uk unknown
- 2016-08-03 ES ES16750223T patent/ES2850298T3/es active Active
- 2016-08-03 MX MX2018001564A patent/MX379530B/es unknown
- 2016-08-03 US US15/227,325 patent/US9758506B2/en active Active
- 2016-08-03 RU RU2018105020A patent/RU2737158C2/ru active
- 2016-08-03 TW TW105124670A patent/TWI723037B/zh active
- 2016-08-03 ES ES20213929T patent/ES2980578T3/es active Active
- 2016-08-03 KR KR1020187006156A patent/KR102664558B1/ko active Active
- 2016-08-03 DK DK16750223.6T patent/DK3331869T3/da active
- 2016-08-03 AU AU2016302048A patent/AU2016302048B2/en active Active
- 2016-08-03 JP JP2018504985A patent/JP6876675B2/ja active Active
- 2016-08-03 CA CA2993484A patent/CA2993484C/en active Active
- 2016-08-03 EP EP20213929.1A patent/EP3822262B1/en active Active
- 2016-08-03 CN CN201680043661.XA patent/CN107949558B/zh active Active
- 2016-08-03 EP EP16750223.6A patent/EP3331869B1/en active Active
-
2017
- 2017-09-08 US US15/699,674 patent/US10351545B2/en active Active
-
2018
- 2018-01-21 IL IL257064A patent/IL257064A/en unknown
- 2018-02-01 US US15/886,057 patent/US10167272B2/en active Active
- 2018-02-01 CL CL2018000292A patent/CL2018000292A1/es unknown
- 2018-02-02 ZA ZA2018/00715A patent/ZA201800715B/en unknown
- 2018-02-02 PH PH12018500259A patent/PH12018500259A1/en unknown
- 2018-02-26 CO CONC2018/0002060A patent/CO2018002060A2/es unknown
-
2019
- 2019-05-21 US US16/418,354 patent/US11091456B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201800715B (en) | Muscarinic agonists | |
| GB201513740D0 (en) | Muscarinic agonist | |
| GB201513743D0 (en) | Muscarinic agonists | |
| AP2016009445A0 (en) | Muscarinic receptor agonists | |
| GB201506827D0 (en) | Composition | |
| GB201505527D0 (en) | Composition | |
| IL254550A0 (en) | Toilet paper roll holder | |
| GB201506825D0 (en) | Composition | |
| GB201504665D0 (en) | Composition | |
| EP3265466A4 (en) | Peripheral-anticholinergic muscarinic agonist combination | |
| GB201522311D0 (en) | Use | |
| GB201522309D0 (en) | Use | |
| GB201504307D0 (en) | Composition | |
| GB201506828D0 (en) | Composition | |
| GB201505520D0 (en) | Composition | |
| PT3370756T (pt) | Combinação de canrenoato e exenatido | |
| GB201521085D0 (en) | Use | |
| GB201506826D0 (en) | Composition | |
| GB201518466D0 (en) | Use | |
| GB201510077D0 (en) | Use | |
| GB201519573D0 (en) | Combination | |
| GB201509839D0 (en) | One piece | |
| GB201500297D0 (en) | Agonists | |
| HUE052800T2 (hu) | Kontrasztanyagok | |
| GB201400386D0 (en) | Agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |